]>
IRCT20200413047053N1 IRCT 2020-04-15 Mashhad University of Medical Sciences Evaluation the effect of asafoetida in the treatment of coronavirus infection Evaluation the effect of asafoetida on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial 2020-04-20 anticipated 60 Complete https://irct.ir/trial/47139 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages: 1- Generation simple or limited randomization will be done based on a table of random numbers 2- Allocation concealment: which is done in the form of coded boxes (numbered drug containers) with a random sequence. In this method, a number of boxes with the same shape and size are numbered based on random sequences and contain drugs or placebo that have a completely similar appearance. 3- Execution of random allocation process: A: Identify the person who creates the random sequence B: A person who evaluates and registers researchers in terms of inclusion and exclusion criteria C: The person who assigned the participants to the groups: infectious diseases specialist The main researcher of the project, who creates a random sequence, does not interfere in other stages of randomization, including registration and allocation of participants, and the person involved in creating a random program is separate from other researchers, Blinding description: the medicine in the form of similar capsule but with the alphabetics A or B will be delivered to physician and patients. 2 Covid-19. Intervention 1: Intervention group1: In addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Khorasan asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention 2: Intervention group2: n addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Fars asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention 3: control group: this group receive placebo capsules exactly with similar characteristics to real drugs in intervention group. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is it is not yet known if there will be a plan to make this availab
public Mehrdad Iranshahi
Blvd vakilabad, school of pharmacy
Mashhad Iran (Islamic Republic of) 9177948954 +98 51 3180 1256 iranshahim@mums.ac.ir Mashhad University of Medical Sciences scientific Mehrdad Iranshahi
Blvd vakilabad
Mashhad Iran (Islamic Republic of) 9177948954 +98 51 3180 1256 iranshahim@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Fever cough Myalgia lymphopenia CRP positive 18 years 65 years Both Sensitivity to asafoetida and it derivatives Patients with hepatic disfunction Patients with renal disfunction Patients with respiratory disorders Patients who take cytotoxic or corticosteroid drugs Nursing women pregnant women U07.1 Covid-19 Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group1: In addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Khorasan asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention group2: n addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Fars asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. control group: this group receive placebo capsules exactly with similar characteristics to real drugs in intervention group. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device. CRP level. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit. Mashhad University of Medical Sciences Approved 2020-04-13 Medical Ethics Committee of Mashhad University of Medical Sciences Blv. Vakilabad2, school of pharmacy, 1368-91775 Mashhad Razavi Khorasan Iran (Islamic Republic of)